Investigators utilized Automated Quantitative Ulcer Analysis to compare microbial keratitis demographics, clinical ...
Collaboration results in platform to help researchers overcome challenges in MSC research ...
Key market opportunities for mesenchymal stem cells include advancements in regenerative medicine, growing investments in R&D ...
BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company”), a clinical-stage ...
R3 Stem Cell's trademark for "Regenerative Trifecta" formalizes the brand identity of a clinical protocol used across ...
Gallant, an animal health biotechnology company pioneering off-the-shelf mesenchymal stromal cell (MSC) therapies for pets, today announced that its canine osteoarthritis (OA) MSC therapy program has ...
INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity ...
Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST)- Pivotal data from Phase 3 PEAK ...
You can shed the kilos and normalise your blood tests, yet your immune cells may still act as if you were obese. Scientists ...
The lining of the human uterus does something no other tissue in the body can match: every month, it tears itself apart, ...
Lung cancer treatment and outcomes are profoundly influenced by the tumor microenvironment (TME), particularly in resectable ...